CDKN2A: The patient undergoes intensive-level skin surveillance inclusive of clinical and instrumental follow-ups every 3 months; in the presence of familial pancreatic cancer (I-II degree) the patient is referred for gastroenterological evaluation and magnetic resonance imaging (MRI) of pancreas and/or an endoscopic ultrasound (ES). This evidence concerns the gene CDKN2A and pancreatic neoplasm.